Formulation and evaluation of alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 12, Issue 4, 2005, Pages 217-222

  Reddy, G Thirumal ^a   Kumar, T M Pramod ^a   Veena, ^b  

^a JSS COLLEGE OF PHARMACY   (India)

^b JSS DENTAL COLLEGE AND HOSPITAL   (India)

Author keywords

Alendronate Sodium; Carbopol 934P; Gels; Periodontitis

Indexed keywords

ALENDRONIC ACID; CARBOMER; METHYL PARABEN; PROPYL PARABEN; TRIETHANOLAMINE; WATER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DIFFUSION; DRUG FORMULATION; DRUG STERILITY; GEL; GINGIVA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PARAMETER; PERIODONTITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VISCOSITY;

ADMINISTRATION, BUCCAL; ADULT; ALENDRONATE; BACTERIA; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DRUG CONTAMINATION; DRUG STABILITY; GELS; HUMANS; MIDDLE AGED; PARTICLE SIZE; PERIODONTITIS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TREATMENT OUTCOME; VISCOSITY;

EID: 22144480665     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/10717540590952663     Document Type: Article

References (11)

1. Binderman, M. A., and Yaffe, A. 2000. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J. Perioden. 71:1236-1240.
2. Esoposital, E., and Carotta, V. 1996. Comparative analysis of tetracycline containing dental gels: Poloxamer and monoglyceride-based formulations. Int. J. Pharm. 142:9-23.
3. Harvey, et al. 2001. United States Patent No. 6, 331, 533 (18 Dec. 2001). Method for inhibiting dental resorptive lesions, 1-81
4. Haydee, B. F. 2002. Use of β-cyclodextrins to prevent modifications of the properties of carbopol gels due to carbopol-drug interaction. Chem. Pharm. Bulletin 50:40-46.
5. Jemberg, G. R. 1997. United States Patent No. 6, 123, 957 (16 July 1997). Delivery of agents and method for regeneration of periodontal tissue, 1-12.
6. Jiunn, H., and Lin et al. 1991. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate in laboratory animals. J. Drug Metabol Dispos. 926-932.
7. Merck Sharp and Dohme (Italy). 2000. Profile on alendronate sodium. Reg. No. Mal 1005100350A, 1-14.
8. Meyyanathan S.N.,and Ramasharma, G. V. S. 2001. Quantitative determination of alendronate sodium in pharmaceutical dosage form and in bulk drug by spectrophotometry. Ind. Drugs 38:461-463.
9. Paulocosta, J. M. S. L. 2001. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:123-133.
10. Tenenbaum, H. C. 2002. Bisphosphonates and periodontics: Potential applications for regulations of bone mass in the periodontium and other therapeutics/diagnostic uses. J. Periodon. 73:813-822.
11. Yaffe, A., and Miztkovich. 1997. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in Rats. J. Periodon. Sep. 68:884-889.